Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study

Journal of Clinical Oncology

Volumn 26, Issue 21, 2008, Pages 3523-3529

  Hochster, Howard S ^a   Hart, Lowell L ^b   Ramanathan, Ramesh K ^b   Childs, Barrett H ^b   Hainsworth, John D ^b   Cohn, Allen L ^b   Wong, Lucas ^b   Fehrenbacher, Louis ^b   Abubakr, Yousif ^b   Saif, M Wasif ^b   Schwartzberg, Lee ^b   Hedrick, Eric ^b  

^a NEW YORK UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CALCIUM; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MAGNESIUM SALT; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSESTHESIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORBIDITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERITONITIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SEPSIS; SEPTIC SHOCK; SMALL INTESTINE OBSTRUCTION; THERAPY DELAY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; ULCER PERFORATION; UNSPECIFIED SIDE EFFECT; VOMITING; WOUND HEALING IMPAIRMENT; ADENOCARCINOMA; COLORECTAL TUMOR; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 49049105525     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.4138     Document Type: Article

References (11)

1. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
2. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
3. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
4. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
5. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
6. Gwyther SG, Therasse P, Arbuck SG, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
7. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an antivascular endothelial cell growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
8. Kozloff M, Cohn A, Christiansen N, et al: Safety of bevacizumab (BV) among patients (pts) receiving first line chemotherapy for metastatic colorectal cancer: Updated results from a large observational study in the U.S. (BRITE). Gastrointestinal Cancers Symposium, 2006 (abstr 247) http://www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID= 41&abstractID=405 Last accessed 20 February 2008
9. Bendell JC, Fernando N, Morse M, et al: A phase II study of oxaliplatin, capecitabine, and bevacizumab in the treatment of metastatic colorectal cancer. J Clin Oncol 24:156s, 2006 (suppl; abstr 3541)
10. Emmanouilides C, Sfakiotaki G, Androulakis N, et al: Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: A multicenter phase II study. BMC Cancer 30;7:91, 2007
11. Saltz L, Clarke S, Diaz-Rubio E, et al: Bevacizumab in combination with XELOX or FOLFOX-4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 25, 2007 (suppl; abstr 4028)